Literature DB >> 20720529

National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events.

George Bakris1, Joseph Vassalotti, Eberhard Ritz, Christoph Wanner, George Stergiou, Mark Molitch, Richard Nesto, George A Kaysen, James R Sowers.   

Abstract

Cardiovascular disease (CVD) is the most common cause of death in industrialized nations. Type 2 diabetes is a CVD risk factor that confers risk similar to a previous myocardial infarction in an individual who does not have diabetes. In addition, the most common cause of chronic kidney disease (CKD) is diabetes. Together, diabetes and hypertension account for more than two-thirds of CVD risk, and other risk factors such as dyslipidemia contribute to the remainder of CVD risk. CKD, particularly with presence of significant albuminuria, should be considered an additional cardiovascular risk factor. There is no consensus on how to assess and stratify risk for patients with kidney disease across subspecialties that commonly treat such patients. This paper summarizes the results of a consensus conference utilizing a patient case to discuss the integrated management of hypertension, kidney disease, dyslipidemia, diabetes, and heart failure across disciplines.

Entities:  

Mesh:

Year:  2010        PMID: 20720529     DOI: 10.1038/ki.2010.292

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  20 in total

1.  Simultaneous deletion of Bax and Bak is required to prevent apoptosis and interstitial fibrosis in obstructive nephropathy.

Authors:  Hee-Seong Jang; Babu J Padanilam
Journal:  Am J Physiol Renal Physiol       Date:  2015-07-15

2.  Changes in serum inflammatory markers are associated with changes in apolipoprotein A1 but not B after the initiation of dialysis.

Authors:  George A Kaysen; Lorien S Dalrymple; Barbara Grimes; Glenn M Chertow; John Kornak; Kirsten L Johansen
Journal:  Nephrol Dial Transplant       Date:  2013-09-05       Impact factor: 5.992

Review 3.  Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease.

Authors:  Rashmee U Shah; Tara I Chang; Gregg C Fonarow
Journal:  Heart Fail Clin       Date:  2012-10-16       Impact factor: 3.179

Review 4.  Nephropathy in youth and young adults with type 2 diabetes.

Authors:  Carolina Solis-Herrera; Curtis L Triplitt; Jane L Lynch
Journal:  Curr Diab Rep       Date:  2014-02       Impact factor: 4.810

5.  Childhood-Adolescent Obesity in the Cardiorenal Syndrome: Lessons from Animal Models.

Authors:  Melvin R Hayden; James R Sowers
Journal:  Cardiorenal Med       Date:  2011-04-12       Impact factor: 2.041

6.  Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.

Authors:  Jinu Kim; Sang Pil Yoon; Myron L Toews; John D Imig; Sung Hee Hwang; Bruce D Hammock; Babu J Padanilam
Journal:  Am J Physiol Renal Physiol       Date:  2014-11-05

Review 7.  Molecular phenotyping of clinical AKI with novel urinary biomarkers.

Authors:  Sarah C Huen; Chirag R Parikh
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-17

Review 8.  Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.

Authors:  Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-08-01       Impact factor: 4.741

9.  Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation.

Authors:  Jinu Kim; John D Imig; Jun Yang; Bruce D Hammock; Babu J Padanilam
Journal:  Am J Physiol Renal Physiol       Date:  2014-08-27

10.  [Non-pharmacological and pharmacological treatment of arterial hypertension: current situation].

Authors:  J Hoyer
Journal:  Herz       Date:  2012-11       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.